HBIO - Harvard Bioscience Inc

HBIO - Harvard Bioscience Inc

https://www.harvardbioscience.com

Recent News

Powered by Alpha Vantage

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors - Harvard Bioscience ( NASDAQ:HBIO )

Benzinga • 6 days, 4 hours ago • score: 0.39

HOLLISTON, Mass., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. HBIO ( the "Company" or "Harvard Bioscience" ) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board's Nominating and ...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

GlobeNewswire • 1 month, 4 weeks ago • score: 0.40

HOLLISTON, Mass., July 17, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. ( Nasdaq: HBIO ) ( the "Company" or "Harvard Bioscience" ) today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective ...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board - Harvard Bioscience ( NASDAQ:HBIO )

Benzinga • 1 month, 4 weeks ago • score: 0.38

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 '25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 '25 gross margin guidance

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

GlobeNewswire • 4 months, 1 week ago • score: 0.24

HOLLISTON, Mass., May 05, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. ( Nasdaq: HBIO ) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.

52W High

$3.04

52W Low

$0.28

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.55

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

14.93

EV/EBITDA (<8 favorable)

179.26

EV/Revenue (<3 favorable)

0.64

P/S (TTM) (<3 favorable)

0.24

P/B (<3 favorable)

1.35

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

10.07%

Institutions (25–75% balanced)

54.77%

Shares Outstanding

44,531,200

Float

33,721,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

88,750,000

Gross Profit (TTM)

50,536,000

EPS (TTM)

-1.29

Profit Margin (>10% good)

-0.65%

Operating Margin (TTM) (higher better)

-0.03%

ROE (TTM) (>15% strong)

-1.38%

EPS YoY (Quarterly) (>10% good)

-0.80

Revenue YoY (Quarterly) (>8% good)

-0.12

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—